Related Experiment Video
Updated: Oct 10, 2025
Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
Published on: November 1, 2017
Liposome-encapsulated anthraquinone improves efficacy and safety in triple negative breast cancer
Thomashire A George1, Max M Chen2, Andreas Czosseck2
1International PhD Program in Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan.
Abstract:
Breast cancer is the most common cancer among women and a leading cause of death worldwide. Triple negative breast cancer (TNBC) is a highly aggressive subtype which is the most challenging to treat. Due to heterogeneity and a lack of specific molecular targets, small molecule-based chemotherapy is the preferred course of treatment. However, these drugs have high toxicity due to off-target effects on healthy tissues, and tumors may develop resistance. Here, we present a polyethylene glycol-modified nanoscale liposomal formulation (LipoRV) of a new anthraquinone derivative which has potent effects on multiple TNBC cell lines. LipoRV readily inhibited the cell cycle, induced cell apoptosis, and reduced long-term proliferative potential of TNBC cells. In a xenograft animal model, LipoRV successfully cleared tumors and demonstrated a good safety profile, without detrimental effects on biochemical markers. Finally, RNA sequencing of LipoRV-treated TNBC cells was carried out, indicating that LipoRV may have immunomodulatory properties. These findings demonstrate that a liposomal anthraquinone-based molecule has excellent promise for TNBC therapy in the future.
Insights
A novel liposomal anthraquinone derivative, LipoRV, effectively targets triple-negative breast cancer (TNBC) by inhibiting cell growth and inducing apoptosis. This promising formulation shows a good safety profile and potential immunomodulatory effects for future TNBC therapies.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options.
- Current chemotherapy for TNBC has high toxicity and can lead to drug resistance.
- There is a critical need for novel, targeted therapies for TNBC.
Purpose of the Study:
- To develop and evaluate a novel polyethylene glycol-modified nanoscale liposomal formulation (LipoRV) of an anthraquinone derivative for TNBC treatment.
- To assess the efficacy and safety of LipoRV against TNBC cell lines and in an animal model.
- To investigate the potential mechanisms of action, including immunomodulatory properties.
Main Methods:
- Synthesis and characterization of LipoRV, a liposomal formulation of an anthraquinone derivative.
- In vitro studies on multiple TNBC cell lines to evaluate cell cycle inhibition, apoptosis induction, and proliferative potential.
- In vivo efficacy and safety assessment using a TNBC xenograft animal model.
- RNA sequencing analysis of LipoRV-treated TNBC cells to explore potential immunomodulatory effects.
Main Results:
- LipoRV demonstrated potent inhibition of TNBC cell proliferation, cell cycle arrest, and induction of apoptosis in vitro.
- LipoRV effectively cleared tumors in a xenograft animal model with a favorable safety profile and no adverse effects on biochemical markers.
- RNA sequencing suggested potential immunomodulatory properties of LipoRV.
Conclusions:
- LipoRV, a liposomal anthraquinone-based molecule, shows significant promise as a novel therapeutic agent for triple-negative breast cancer.
- The formulation exhibits potent anti-cancer activity, a good safety profile, and potential immunomodulatory effects, warranting further clinical investigation.
- LipoRV represents a potential advancement in the treatment of challenging TNBC cases.
